Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
AX Zhu, AR Abbas, MR de Galarreta, Y Guan, S Lu…�- Nature medicine, 2022 - nature.com
Atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular
endothelial growth factor (VEGF)) combination therapy has become the new standard of�…
endothelial growth factor (VEGF)) combination therapy has become the new standard of�…
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
AX Zhu, AR Abbas, MR de Galarreta, Y Guan, S Lu… - paper.sciencenet.cn
Atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular
endothelial growth factor (VEGF)) combination therapy has become the new standard of�…
endothelial growth factor (VEGF)) combination therapy has become the new standard of�…
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
AX Zhu, AR Abbas, MR de Galarreta…�- Nature�…, 2022 - mdanderson.elsevierpure.com
Atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular
endothelial growth factor (VEGF)) combination therapy has become the new standard of�…
endothelial growth factor (VEGF)) combination therapy has become the new standard of�…
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
AX Zhu, AR Abbas, MR de Galarreta…�- Nature�…, 2022 - pubmed.ncbi.nlm.nih.gov
Atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular
endothelial growth factor (VEGF)) combination therapy has become the new standard of�…
endothelial growth factor (VEGF)) combination therapy has become the new standard of�…
[CITATION][C] Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
AX Zhu, AR Abbas, MR de Galarreta, Y Guan, S Lu…�- Nature Medicine, 2022 - cir.nii.ac.jp
Molecular correlates of clinical response and resistance to atezolizumab in combination with
bevacizumab in advanced hepatocellular carcinoma | CiNii Research CiNii 国立情報学研究所�…
bevacizumab in advanced hepatocellular carcinoma | CiNii Research CiNii 国立情報学研究所�…
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.
AX Zhu, AR Abbas, MR de Galarreta, Y Guan…�- Nature�…, 2022 - europepmc.org
Atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular
endothelial growth factor (VEGF)) combination therapy has become the new standard of�…
endothelial growth factor (VEGF)) combination therapy has become the new standard of�…